Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Research and Markets
DUBLIN, February 5, 2014 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/3vvhng/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market - Forecasts to 2016" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011.
According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed.
Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
1. Executive Summary
2. List of Abbreviations
4. Market Research Methodology
5. Scope of the Report
6. Market Landscape
7. Key Market Segmentation
8. Geographical Segmentation
9. Key Leading Countries
10. Vendor Landscape
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Key Vendor Analysis
18. Other Reports in this Series
For more information visit http://www.researchandmarkets.com/research/3vvhng/global
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
©2012 PR Newswire. All Rights Reserved.